Sunshine Biopharma wins Canadian approval for generic Dienogest tablets

PUBT · 2d ago
Sunshine Biopharma wins Canadian approval for generic Dienogest tablets
  • Sunshine Biopharma secured Canadian regulatory clearance for generic dienogest 2 mg tablets, a Visanne equivalent for endometriosis-related pelvic pain.
  • The company expects product shipments to Canadian pharmacies by end-2026 through its Nora Pharma distribution network.
  • Dataintelo estimates the global dienogest market at USD 2.8 billion in 2025, rising to USD 5.2 billion by 2034.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein.